PAPER DETAILS

TITLE: Synthesis of Geranyloxycoumarin Derivatives under Mild Conditions Using Cs2CO3

AUTHORS: Sumi HWANG, Eonjoo ROH

PAGES: 57-66

ORIGINAL PDF URL: https://dergipark.org.tr/tr/download/article-file/1977960



Synthesis of Geranyloxycoumarin Derivatives under Mild Conditions Using Cs₂CO₃

SuMi Hwang¹ (D) and EonJoo Roh²* (D)

¹Sangji University, Department of Clinical Pathology, Won-ju 26339, Republic of Korea; zzz0722@hanmail.net (S.M.H)

²Changwon National University, Interdisciplinary Program in Biotechnology, Graduate School, Changwon 51140, Republic of Korea; medlife99@gmail.com (E.J.R)

Abstract: In this study, the synthesis of various geranyloxycoumarin derivatives from hydroxycoumarin was obtained in good yield under mild conditions using Cs₂CO₃. In the synthesis of geranyloxycoumarin derivatives, when 4-hydroxycoumarin reacts with geranyl bromide under mild conditions due to tautomeric keto-enol forms, 4-geranyoxycoumarin (3a), C-alkylated coumarin (3aa) and structure 3ab formed by hydrolysis and decarboxylation from 3aa were formed products. In addition, the alkylation reaction of 3-OH, 5-OH, 6-OH, 7-OH, and 8-OH coumarin except 4-OH group produced a high yield.

Keywords: Geranyloxycoumarin derivatives; 4-hydroxycoumarin; tautomeric keto-enol forms; coumarin compounds; geranyl bromide.

Submitted: September 18, 2021. Accepted: November 23, 2021.

Cite this: Hwang S, Roh E. Synthesis of Geranyloxycoumarin Derivatives under Mild Conditions Using Cs2CO3. JOTCSA. 2022;9(1):57–66.

DOI: <u>https://doi.org/10.18596/jotcsa.996363</u>.

***Corresponding author. E-mail:** <u>medlife99@gmail.com</u>, <u>no670@changwon.ac.kr</u>. Tel.: +82-10-7247-9996.

INTRODUCTION

Coumarin and its derivatives are widely used in the synthesis of bioactive molecules (1). The derivatives also show a broad spectrum of beneficial effects, such as anti-inflammatory (2–6), anti-HIV (7–9), anticancer (10–15), antimicrobial (16–18), antitumor (19–23), anti-platelet (24), COX inhibitors (25), antioxidant (26–33), and antibacterial (34,35) activities.

Among them, hydroxylated coumarin secondary metabolites are essential in the synthesis of various geranyloxycoumarins, derivatives, such with outstanding bioactivities. Well known naturally occurred geranyloxycoumarins 7are geranyloxycoumarin (auraptene) isolated from Poncirus trifoliata Rafinesque and 5-geranyloxy-7bergamottin methoxycoumarin, (geranyloxypsoralen) Citrus isolated from

aurantifolia (36).

Coumarin secondary metabolites with hydroxy group are critical in the synthesis of various derivatives outstanding bioactivity. with 4-Hydroxycoumarin and the synthesis its of derivatives first attracted the attention of Shah V.R. et al. in 1960 (36) and 4-hydroxycoumarin has since been used for producing a variety of coumarin derivatives based on its keto-enol tautomeric properties (37). The alkylation of the coumarin without the 4-OH group has also been investigated as a general method of synthesis. The alkylation reaction of the hydroxycoumarins has been investigated as a general method of synthesis of geranyloxycoumarins but, on the best of our view, the reaction strongly depended on the position of the hydroxy group, base additive, and reaction conditions. Interestingly, 4-hydroxycoumarin has since been used for producing a variety of O-4 and C-3 coumarin derivatives based on its keto-enol In this study, the reaction between hydroxycoumarins (1) and geranyl bromide (2) was studied in the synthesis of geranyloxycoumarin derivatives (3), using both weak and strong basic additives such as K_2CO_3 , Cs_2CO_3 , and Ag_2CO_3 , respectively. The C-3 and O-4 alkylation of the 4-hydroxycoumarin under mild optimized reaction condition has also been investigated.

EXPERIMENTAL

General Experimental Procedures

The silica gel 60 (230-400 mesh ASTM, 0.040-0.063 mm) for open chromatography and GF₂₅₄ for TLC were purchased from Merck Ltd. (Darmstadt, Germany). All solvents and chemicals used in this studv were of analytical grade. For the hydroxycoumarin derivatives with a different 4-hydroxy-3substituent (4-hydroxycoumarin, nitrocoumarin, 3-hydroxycoumarin, 6hydroxycoumarin, 7-hydroxycoumarin, 3-3-chloro-7-hydroxy-4phenylumbelliferone, methylcoumarin and 6-chloro-7-hydroxy-4methylcoumarin), the commercially available, 97%-98% pure TCI (Japan) and Alfa Aesar (USA) products were used. The established methods of synthesis were used to obtain 4-methyl-7hydroxycoumarin (39,41), 6-hydroxy-4methylcoumarin (39,41), 7-hydroxy-4trifluoromethylcoumarin (39,41) and 4-methyl-6,7dihydroxycoumarin (39,41). The alkenyl chain used in the synthesis of geranyloxycoumarin derivatives was 95% geranyl bromide (Aldrich, USA). For the base. NaOH, K₂CO₃, Cs_2CO_3 , Ag₂CO₃ and triethylamine (Et₃N) were used, whereas the solvents used in this study were ethyl acetate (EtOAc), acetonitrile, n-hexane, dichloromethane (DCM), ethanol (EtOH), and acetone. Nuclear magnetic spectrometer resonance (NMR spectrometer; BRUKER AVANCE 400 MHz, BRUKER, Germany) was used for analysis. CDCl₃ containing tetramethylsilane (TMS), which is an internal standard, was used as analytical solvent. Chemical shifts (δ) are given in parts per million (ppm), and coupling constants (J) are in hertz (Hz). Residual central signals of CDCl₃ were recorded as follows: δ H = 7.26, δ C = 77.00. Infrared spectroscopy was performed, in the form of KBr pellets, on FT/IR-4200 (JASCO, Japan) spectrophotometer, to confirm the functional groups in the compound. Highresolution mass spectra were recorded on an SCIEX 3200) liquid-chromatography-mass (Otrap spectrometer (USA). In addition, the melting point was measured without calibrating the temperature. A thermometer was mounted under a paraffin oil container, and the open glass capillary method was used.

Common synthesis method of geranyloxycoumarin derivative

To a stirred mixture of hydroxycoumarin 1a (1.0 mmol) and powdered cesium carbonate (1.1 mmol) in acetonitrile (30 mL), geranyl bromide with 95% purity (1.2 mmol) was added, and the stirring was continued at RT for 3 hours. The reaction progress was monitored using TLC. When the reaction finished the solvent was removed under reduced pressure, then DCM (20 mL) was added to the mixture which was filtered off. After the evaporation of the solvent, crude products were purified by column chromatography on silica gel eluted with the mixture of n-hexane:DCM (1:1, v/v) to obtain pure geranyloxycoumarins (E)-4-(3,7-dimethylocta-2,6dienyloxy)-2Hchromen-2-one (3a), 3,3-bis((E)-3,7dimethylocta-2,6-dien-1-yl)chromane-2,4-dione (3aa), and (E)-2-((E)-3,7-dimethylocta-2,6-dien-1yl)-1-(2-hydroxyphenyl)-5,9-dimethyldeca-4,8-dien-1-one (3ab).

Characterization of (3a) (44)

White powder, Yield: 18%; m.p. 47-48 °C; IR (KBr, cm⁻¹): v 2923 (Aliphatic C-H), 1718 (C=O), 1620, 1371, 1235 (C-O), 1182 (C-O), 1104 (C-O), 923, 817, 764, 751, 500; ¹H-NMR (400 MHz, CDCl₃): δ 1.62 (s, 3H, CH₃), 1.69 (s, 3H, CH₃), 1.77 (s, 3H, CH₃), 2.08–2.18 (m, 4H, -CH₂CH₂-), 4.71 (d, J =6.7 Hz, 2H, -CH₂-), 5.08-5.12 (m, 1H, =CH), 5.51 (t, J = 6.7 Hz, 1H, =CH), 5.69 (s, 1H, H-3), 7.25-7.33 (m, 2H, H-6 and H-8), 7.53-7.57 (m, 1H, H-7), 7.84 (dd, J = 2.2 Hz, 5.8Hz, 1H, H-5) ppm; ¹³C-**NMR** (100 MHz, CDCl₃): δ 16.82 (CH₃), 17.75 (CH₃), 25.70 (CH₃), 26.19 (CH), 39.50 (CH), 66.27 (CH), 90.64 (CH), 115.92 (C), 116.75 (CH), 117.06 (CH), 123.19 (CH), 123.46 (CH), 123.83 (CH), 132.13 (CH), 132.31 (C), 143.74 (C), 153.35 (C), 163.15 (C), 165.61 (C) ppm; MS (EIMS): m/z 298 [M]⁺; Anal. Calcd for C₁₉H₂₂O₃: C, 76.48; H, 7.43, Found: C, 76.49; H, 7.40.

Characterization of (3aa) (43)

Colorless liquid, Yield: 11%; IR (KBr, cm⁻¹): v 2966 (Aliphatic C-H), 2917 (Aliphatic C-H), 2854 (Aliphatic C-H), 1772 (C=O), 1689 (C=O), 1611, 1461, 1288 (C-O), 1142, 755; ¹H-NMR (400 MHz, CDCl₃): δ 1.47 (s, 6H, 2CH₃), 1.55 (s, 6H, 2CH₃), 1.59 (s, 6H, 2CH₃), 1.79 (s, 8H, 2(-CH₂CH₂-)), 2.70-2.80 (m, 2H, -CH₂-), 2.82-2.89 (m, 2H, -CH₂-), 4.86-4.95 (m, 4H, 4 (=CH)), 7.15 (dd, J = 2.5 Hz, 8.0 Hz, 1H, H-8), 7.21-7.25 (m, 1H, H-5), 7.58-7.63 (m, 1H, H-7), 7.91 (dd, J = 2.5 Hz, 8.0 Hz,1H, H-5) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 16.21 (CH₃), 17.52 (CH₃), 25.49 (CH₃), 26.33 (CH), 37.62 (CH), 39.65 (CH), 62.24 (C), 116.89 (CH), 117.49 (C), 119.53 (CH), 123.78 (CH), 124.66 (CH), 126.55 (CH), 131.32 (C), 136.82 (C), 140.59 (C), 154.89 (C), 170.56 (C), 194.66 (C) ppm; MS (EIMS): m/z 434 [M]+; Anal. Calcd for C₂₉H₃₈O₃: C, 80.14; H, 8.81, Found: C, 80.09; H, 8.76.

Synthesis method of (3ab)

To a stirred mixture of 3aa (2.3 mmol) and powdered cesium carbonate (2.5)mmol) in acetonitrile (30 mL), distilled water (2.6 mmol6mmol) was added, and the stirring was continued at RT for 9 hours. The reaction progress was monitored using TLC. When the reaction finished the solvent was removed under reduced pressure, then DCM (20 mL) was added to the mixture which was filtered up. After evaporation of the solvent crude products were filtered by column chromatography on silica gel eluted with the mixture of n-hexane:DCM (3:1, v/v) to obtain pure 3ab.

Characterization of (3ab)

Colorless liquid, Yield : 35%; IR (KBr, cm⁻¹): v 1712 (-C=O); ¹H-NMR (400MHz, CDCl₃): δ 1.54 (s, 6H, 2CH₃), 1.58 (s, 6H, 2CH₃), 1.62 (s, 6H, 2CH₃), 1.84-1.98 (m, 8H, 2(-CH₂CH₂-)), 2.25-2.32 (m, 2H, -CH₂-), 2.41–2.48 (m, 2H, -CH₂-), 3.47–3.54 (m, 1H, -C-H), 4.98–5.03 (m, 2H, 2(=C-H)), 5.06– 5.11(m, 2H, 2(=C-H)), 6.86-6.90 (m, 1H), 6.95-6.98 (m, 1H), 7.42-7.46 (m, 1H), 7.76-7.79 (dd, J = 1.8 Hz, 8.2 Hz, 1H), 12.66 (s, 1H, OH, D₂O exch.) ppm; 13 C-NMR (100MHz, CDCl₃): δ 16.10 (CH₃), 17.67 (CH₃), 25.65 (CH₃), 26.54 (CH₂), 30.60 (CH₂), 39.74 (CH₂), 46.39 (CH), 118.56 (CH), 118.68 (CH), 119.65 (C), 121.10 (CH), 124.11 (CH), 130.24 (CH), 131.45 (C), 136.20 (CH), 137.59 (C), 162.93 (C), 210.28 (-C=O) ppm; MS (EIMS): m/z 408 [M]+; Anal. Calcd for C₂₈H₄₀O₂: C, 82.30; H, 9.87, Found: C, 82.27; H, 8.88.

Common synthesis method of geranyloxycoumarin derivatives

To a stirred mixture of hydroxycoumarin 1b-1l (1.0 mmol) and powdered cesium carbonate (1.1 mmol) in acetonitrile (30 mL), 95% geranyl bromide (1.2 mmol was added, and the stirring was continued at RT for 2.5-34 hours. The reaction progress was monitored using TLC. When the reaction finished the solvent was removed under reduced pressure, then DCM (20 mL) was added to the mixture which was filtered up. After evaporation of the solvent crude products were filtered by column chromatography on silica gel eluted with the mixture of nhexane:DCM (1:1,v/v) to obtain pure geranyloxycoumarin 3c-3l.

Characterization of (3c)

White solid, Yield: 90%; m.p. 62–63 °C; **IR** (KBr, cm⁻¹): v 3077 (Aromatic C-H), 3030 (Aromatic C-H), 2974 (Aliphatic C-H), 2914 (Aliphatic C-H), 2894 (Aliphatic C-H), 1730 (Carbonyl (ester -C=O)), 1609 (C=C bond), 1556, 1516, 1452, 1427, 1400, 1351, 1275, 1215, 1192, 1166, 1137, 1014, 999, 958, 872, 818, 781, 715, 649, 626 ; ¹H-NMR (400 MHz, CDCl₃): δ 1.57 (s, 3H, CH₃), 1.62 (s, 3H, CH₃), 1.73 (s, 3H, CH₃), 2.03–2.13 (m, 4H, -CH₂CH₂-), 4.59 (d, J = 4.0 Hz, -OCH₂-), 5.01–5.06 (m, 1H, =CH),

5.40–5.45 (m, 1H, =CH), 6.57 (s, 1H, H-3), 6.83 (d, J = 2.5 Hz, 1H, H-8), 6.88 (dd, J = 2.5 Hz, 9.0 Hz, 1H, H-6), 7.56–7.59 (m, 1H, H-5) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 16.79 (CH₃), 17.70 (CH₃), 25.65 (CH₃), 26.20 (CH₂), 39.50 (CH₂), 65.67 (CH₂), 102.13 (CH), 106.88 (CH), 112.04 (q, $^{3}J_{CF} = 5.7$ Hz), 113.98 (C), 120.25 (CH), 123.00 (CH), 123.54 (CH), 126.24 (q, $^{3}J_{CF} = 2.0$ Hz, CH), 132.02 (C), 141.61 (q, $^{2}J_{CF} = 32.7$ Hz, CCF₃), 142.78 (C), 156.31 (C), 159.49 (C), 162.86 (C) ppm; ¹⁹F-NMR (470 MHz, DMSO-d₆): δ 63.62 (s, 3F) ppm; MS (EIMS): m/z 366 [M]⁺; Anal. Calcd for C₂₀H₂₁F₃O₃: C, 65.57; H, 5.78, Found: C, 65.54; H, 5.76.

Characterization of (3d) (44)

White solid, Yield: 93%; m.p. 66-67 °C; IR (KBr, cm⁻¹): v 3082 (Aromatic C-H), 3053 (Aromatic C-H), 2972 (Aliphatic C-H), 2896 (Aliphatic C-H), 2879 (Aliphatic C-H), 2849 (Aliphatic C-H), 2833 (Aliphatic C-H), 1728 (Carbonyl (ester -C=O)), 1611 (C=C bond), 1507, 1452, 1430, 1403, 1369, 1348, 1280, 1234, 1201, 1165, 1126, 1103, 1022, 990, 889, 852, 830, 776, 760; ¹H-NMR (400 MHz, CDCl₃): δ 1.60 (s, 3H, CH₃), 1.66 (s, 3H, CH₃), 1.75 (s, 3H, CH₃), 2.06–2.15 (m, 4H, -CH₂CH₂-), 4.59 (d, J = 6.7 Hz, 2H, -CH₂-), 5.05–5.09 (m, 1H, =CH), 5.44-5.48 (m, 1H, =CH), 6.24 (d, J = 9.5 Hz, 1H, H-3), 6.81 (d, J = 2.5 Hz, 1H, H-6), 6.84 (dd, J = 2.4 Hz, 8.4 Hz, 1H, H-8), 7.36 (d, J = 8.6 Hz, 1H, H-5), 7.63 (d, J = 9.5 Hz, 1H, H-4) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 16.37 (CH₃), 17.31 (CH₃), 25.26 (CH₃), 25.82 (CH₂), 39.11 (CH₂), 65.08 (CH₂), 101.18 (CH), 112.01 (CH), 112.56 (C), 112.84 (CH), 117.99 (CH), 123.20 (CH), 128.26 (CH), 131.57 (C), 141.98 (C), 143.04 (CH), 155.47 (C), 160.90 (C), 161.74 (C) ppm; MS (EIMS): m/z 296 [M]⁺; Anal. Calcd for C₁₉H₂₂O₃: C, 76.48; H, 7.43, Found: C, 76.45; H, 7.41.

Characterization of (3e) (45)

White solid, Yield: 91%; m.p. 54-55 °C; IR (KBr, cm⁻¹): v 3078 (Aromatic C-H), 3028 (Aromatic C-H), 2964 (Aliphatic C-H), 2917 (Aliphatic C-H), 2856 (Aliphatic C-H), 1726 (Carbonyl (ester -C=O)), 1617 (C=C bond), 1508, 1441, 1420,1390, 1345, 1278, 1257, 1199, 1154, 1134, 1070, 992, 982, 843, 825; ¹**H-NMR** (400 MHz, CDCl₃): δ 1.57 (s, 3H, CH₃), 1.63 (s, 3H, CH₃), 1.73 (s, 3H, CH₃), 2.03-2.13 (m, 4H, -CH₂CH₂-), 2.37 (d, J = 1.1 Hz, 3H, CH₃), 4.57 $(d, J = 6.5 Hz, 2H, -CH_2-), 5.03-5.07 (m, 1H,$ =CH), 5.42-5.46 (m, 1H, =CH), 6.10 (q, J = 1,2 Hz, 2.4 Hz, 1H, H-3), 6.79 (d, J = 2.5 Hz, 8.8 Hz, 1H, H-8), 6.84 (d, J = 2.5 Hz, 1H, H-6), 7.46 (dd, J = 2.6 Hz, 8.8 Hz, 1H, H-5) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 16.79 (CH₃), 17.73 (CH₃), 18.70 (CH₃), 25.68 (CH₃), 26.24 (CH₂), 39.53 (CH₂), 65.44 (CH₂), 101.59 (CH), 111.85 (CH), 112.94 (C), 113.47 (CH), 118.45 (CH), 123.63 (CH), 125.46 (CH), 131.97 (C), 142.35 (C), 152.61 (C), 155.25 (C), 161.41 (C), 161.95 (C) ppm ; MS (EIMS): m/z 312 [M]⁺; Anal. Calcd for $C_{20}H_{24}O_3$: C, 76.89; H, 7.74, Found: C, 76.88; H, 7.72.

Characterization of (3f) (46)

Light yellow solid, Yield: 93%; m.p. 136-137 °C; IR (KBr, cm⁻¹): v 3076 (Aromatic C-H), 3027 (Aromatic C-H), 2960 (Aliphatic C-H), 2909 (Aliphatic C-H), 2851 (Aliphatic C-H), 1720 (Carbonyl (ester -C=O)), 1604 (C=C bond), 1600 (C=C bond), 1548, 1505, 1453, 1378, 1354, 1262, 1257, 1208, 1169, 1142, 1077, 1008, 946, 873, 818, 753, 583; ¹H-NMR (400 MHz, CDCl₃): δ 1.60 (s, 3H, CH₃), 1.66 (s, 3H, CH₃), 1.76 (s, 3H, CH₃), 2.06–2.17 (m, 4H, - CH_2CH_2 -), 2.54 (s, 3H, CH_3), 4.60 (d, J = 6.6 Hz, -CH₂-), 5.05–5.09 (m, 1H, =CH), 5.43–5.48 (m, 1H, =CH), 6.82 (d, J = 2.5 Hz, 1H, H-8), 6.90 (dd, J = 2.5 Hz, 8.9 Hz, 1H, H-6), 7.51 (d, J = 8.9 Hz, 1H, H-5) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 16.12 (CH₃), 16.74 (CH₃), 17.66 (CH₃), 25.62 (CH₃), 26.18 (CH₂), 39.46 (CH₂), 65.50 (CH₂), 101.44 (CH), 113.10 (CH), 113.56 (C), 117.60 (CH), 118.24 (CH), 123.54 (CH), 125.74 (CH), 131.93 (C), 142.46 (C), 147.96 (C), 153.04 (C), 157.47 (C), 161.82 (C) ppm ; MS (EIMS): m/z 346 [M]⁺; Anal. Calcd for C20H23ClO3: C, 69.26; H, 6.68, Found: C, 68.70; H, 6.62.

Characterization of (3g)

White solid, Yield: 90%; m.p. 95-96 °C; IR (KBr, cm⁻¹): v 3078 (Aromatic C-H), 3003 Aromatic C-H), 2965 (Aliphatic C-H), 2916 (Aliphatic C-H), 2856 2854 (Aliphatic C-H), 1728 (Aliphatic C-H), (Carbonyl (ester -C=O)), 1609 (C=C bond), 1494, 1414, 1388, 1378, 1320, 1274, 1205, 1157, 1083, 1047, 982, 883, 829; ¹**H-NMR** (400 MHz, CDCl₃): δ 1.59 (s, 3H, CH₃), 1.65 (s, 3H, CH₃), 1.77 (s, 3H, CH₃), 2.06–2.15 (m, 4H, -CH₂CH₂-), 2.38 (d, J =1.2 Hz, 3H, CH₃), 4.69 (d, J = 6.4Hz, 2H, -CH₂-), 5.04-5.08 (m, 1H, =CH), 5.44-5.48 (m, 1H, =CH), 6.16 (dd, J = 1.4 Hz, 2.6 Hz, 1H, H-3), 6.83 (s, 1H), 7.56 (s, 1H) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 16.89 (CH₃), 17.73 (CH₃), 18.65 (CH₃), 25.65 (CH₃), 26.19 (CH₂), 39.50 (CH₂), 66.63 (CH₂), 101.57 (CH), 112.74 (CH), 113.65 (C), 118.03 (CH), 119.34 (C), 123.54 (CH), 125.32 (CH), 132.01 (C), 142.66 (C), 151.70 (C), 153.52 (C), 156.93 (C), 160.79 (C) ppm; MS (EIMS): m/z 346 [M]+; Anal. Calcd for C₂₀H₂₃ClO₃: C, 69.26; H, 6.68, Found: C, 69.00; H, 6.64.

Characterization of (3h)

White solid, Yield: 92%; m.p. 104–105 °C; **IR** (KBr, cm⁻¹): v 3054 (Aromatic C-H), 3036 (Aromatic C-H), 2965 (Aliphatic C-H), 2909 (Aliphatic C-H), 2851 (Aliphatic C-H), 1707 (Carbonyl (ester -C=O)), 1606 (C=C bond), 1503, 1450, 1443, 1429, 1365, 1272, 1220, 1178, 1123, 1105, 1012, 990, 941, 827, 784, 691, 630; **¹H-NMR** (400 MHz, CDCl₃): δ 1.59 (s, 3H, CH₃), 1.66 (s, 3H, CH₃), 1.75 (s, 3H, CH₃), 2.05–2.15 (m, 4H, -CH₂CH₂-), 4.60 (d, *J* = 8.0 Hz, 2H, -CH₂-), 5.05–5.09 (m, 1H, =CH), 5.44–5.48 (m,

1H, =CH), 6.84–6.87 (m, 2H, H-6 and H-8), 7.34– 7.44 (m, 4H), 7.65–7.68 (m, 2H), 7.74 (s, 1H, H-4) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 16.76 (CH₃), 17.69 (CH₃), 25.64 (CH₃), 26.20 (CH₂), 39.48 (CH₂), 65.47 (CH₂), 101.12 (CH), 113.19 (CH), 113.39 (CH), 118.38 (CH), 123.58 (C), 124.63 (CH), 128.36 (CH), 128.39 (CH), 128.74 (CH), 131.94 (C), 135.03 (C), 140.06 (C), 142.34 (CH), 155.23 (C), 160.95 (C), 161.88 (C) ppm; **MS** (**EIMS**): m/z 374 [M]⁺; Anal. Calcd for C₂₅H₂₆O₃: C, 80.18; H, 7.00, Found: C, 80.16; H, 6.99.

Characterization of (3i) (44,47)

White solid, Yield: 92%; m.p 95-96 °C; IR (KBr, cm⁻¹): v 3067 (Aromatic C-H), 3050 (Aromatic C-H), 2958 (Aliphatic C-H), 2911 (Aliphatic C-H), 2870 (Aliphatic C-H), 2840 (Aliphatic C-H), 1704 (Carbonyl (ester -C=O)), 1566 (C=C bond), 1490, 1443, 1385, 1276, 1175, 1171, 1110, 1017, 922, 882, 816, 706; ¹**H-NMR** (400 MHz, CDCl₃): δ 1.60 (s, 3H, CH₃), 1.66 (s, 3H, CH₃), 1.74 (s, 3H, CH₃), 2.06-2.16 (m, 4H, -CH₂CH₂-), 4.56 (d, J = 6.6 Hz, 2H, -CH₂-), 5.05-5.10 (m, 1H, =CH), 5.45-5.50 (m, 1H, =CH), 6.42 (d, J = 9.4 Hz, 1H, H-3), 6.92 (d, J = 2.9 Hz, 1H, H-5), 7.12 (dd, J = 2.9 Hz, 9.0 Hz, 1H, H-7), 7.26 (d, J = 9.0 Hz, 1H, H-8), 7.64 (d, J = 9.5 Hz, 1H, H-4) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 16.74 (CH₃), 17.73 (CH₃), 25.70 (CH₃), 26.25 (CH₂), 39.53 (CH₂), 65.57 (CH₂), 111.08 (CH), 117.02 (CH), 117.83 (CH), 118.90 (CH), 119.15 (CH), 120.15 (C), 123.65, 131.95 (C), 141.96 (C), 143.28 (CH), 148.41 (C), 155.34 (C), 161.05 (C) ppm; MS (EIMS): m/z 298 [M]+; Anal. Calcd for C19H22O3: C, 76.48; H, 7.43, Found: C, 76.46; H, 7.42.

Characterization of (3j)

White solid, Yield: 89%; m.p. 57-58 °C; IR (KBr, cm⁻¹): v 3040 (Aromatic C-H), 2965 (aliphatic C-H), 2925 (aliphatic C-H), 2884 (aliphatic C-H), 1712 (C=O), 1673, 1571, 1493, 1428, 1386, 1275, 1238 (C-O), 1167, 990, 926, 838; ¹H-NMR (400 MHz, CDCl₃): δ 1.60 (s, 3H, CH₃), 1.67 (s, 3H, CH₃), 1.77 (s, 3H, CH₃), 2.06-2.17 (m, 4H, -CH₂CH₂-), 2.41 (d, J = 1.2 Hz, 3H, CH₃), 4.59 (d, J = 6.6 Hz, 2H, CH₂-), 5.06-5.10 (m, 1H, =CH), 5.47-5.51 (m, 1H, =CH), 6.30 (q, J = 1.4 Hz, 2.6 Hz, 1H, H-3), 7.04 (d, J = 2.9 Hz, 1H, H-5), 7.13 (dd, J = 2.9 Hz, 9.0 Hz, 1H, H-7), 7.27 (d, J = 9.0 Hz, 1H, H-8) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 16.74 (CH₃), 17.72 (CH₃), 18.74 (CH₃), 25.68 (CH₃), 26.27 (CH₂), 39.55 (CH₂), 65.56 (CH₂), 108.82 (CH), 115.44 (CH), 117.89 (CH), 119.00 (CH), 119.32 (C), 120.43 (CH), 123.64 (CH), 131.96 (C), 141.96 (C), 147.84 (C), 152.02 (C), 155.20 (C), 161.03 (C) ppm; MS (EIMS): m/z 312 [M]+; Anal. Calcd for C₂₀H₂₄O₃: C, 76.89; H, 7.74, Found: C, 76.86; H, 7.75.

Characterization of (3k)

White solid, Yield: 86%; m.p. 63-64 °C; IR (KBr,

cm⁻¹): v 3065 (Aromatic C-H), 2937 (Aliphatic C-H), 2917 (Aliphatic C-H), 2854 (Aliphatic C-H), 1708 (Carbonyl (ester -C=O)), 1612 (C=C bond), 1562, 1520, 1430, 1384, 1280, 1231, 1164, 984, 822; ¹**H-NMR** (400 MHz, CDCl₃): δ 1.59 (s, 6H, 2CH₃), 1.64 (s, 6H, 2CH₃), 1.77 (s, 6H, 2CH₃), 2.06-2.15 $(m, 8H, 2(-CH_2CH_2-)), 2.37 (d, J = 1.2 Hz, 3H)$ CH_3), 4.67 (d, J = 6.4 Hz, 4H, 2(- CH_2 -)), 5.04–5.08 (m, 2H, 2(=CH)), 5.44-5.48 (m, 2H, 2(=CH)), 6.15 (dd, J = 1.4 Hz, 2.64 Hz, 1H, H-3), 6.83 (s, 1H, H-5), 7.55 (s, 1H, H-8) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 17.04 (CH₃), 17.17 (CH₃), 18.01 (CH₃), 19.14 (CH₃), 25.95 (CH₃), 26.52 (CH₃), 26.59 (CH₃), 39.81 (CH₂), 39.86 (CH₂), 66.63 (CH₂), 67.16 (CH₂), 101.75 (CH), 108.76 (CH), 112.37 (C), 112.65 (CH), 119.06 (CH), 119.92 (C), 123.96 (CH), 132.22 (C), 141.50 (C), 141.91 (C), 145.76 (C), 149.76 (C), 152.70 (C), 153.07 (C), 161.95 (C) ppm; MS (EIMS): m/z 464 [M]+; Anal. Calcd for C₃₀H₄₀O₄: C, 77.55; H, 8.68, Found: C, 77.54; H, 8.66.

Characterization of (3I) (44)

White solid, Yield: 87%; m.p. 72–73 °C; **IR** (KBr, cm⁻¹): v 3086 (Aromatic C-H), 3052 (Aromatic C-H), 2975 (Aliphatic C-H), 2917 (Aliphatic C-H), 2885 (Aliphatic C-H), 1745 (Carbonyl (ester -C=O)), 1638 (C=C bond), 1585, 1503, 1468, 1446, 1413, 1390, 1331, 1319, 1225, 1218, 1164, 1122, 996, 950, 938, 900, 864, 790, 761, 603; ¹H-NMR (400 MHz, CDCl₃): δ 1.57 (s, 3H, CH₃), 1.62 (s, 3H, CH₃), 1.73 (s, 3H, CH₃), 2.03–2.13 (m, 4H, -CH₂CH₂-), 4.61 (d, *J* = 8.0 Hz, 2H, -CH₂-), 5.02–5.06 (m, 1H, =CH), 5.46–5.51 (m, 1H, =CH), 6.79 (s, 1H, H-4), 7.20–7.28 (m, 2H, H6 and H-8), 7.32–7.37 (m, 2H, H-5 and H-7) ppm; ¹³C-NMR (100 MHz, CDCl₃): δ 16.82

.

.

(CH₃), 17.72 (CH₃), 25.66 (CH₃), 26.17 (CH), 39.50 (CH), 66.24 (CH), 113.69 (CH), 116.29 (CH), 117.96 (C), 119.82 (CH), 123.59 (C), 124.64 (CH), 126.37 (CH), 128.33 (CH), 132.00 (CH), 142.51 (C), 143.69 (C), 149.53 (C), 157.77 (C) ppm; **MS** (EIMS): m/z 298 [M]⁺; Anal. Calcd for $C_{19}H_{22}O_3$: C, 76.48; H, 7.43, Found: C, 76.44; H, 7.42.

RESULTS AND DISCUSSION

In this study, our first goal was to identify the optimal conditions for obtaining O-alkylated geranyloxycoumarin derivatives by reaction between hydroxycoumarin and geranyl bromide (Table 1). At first, the reaction between 7-hydroxycoumarin (1d) and geranyl bromide (2) was performed in the presence of Et₃N in acetone at RT to give tarry mixture unidentified degradation products (Table 1, Entry 1). Secondly, when changing to K₂CO₃ instead of TEA, the desired product 3d was obtained in a low 35% yield with 5 hours reaction time (Table 1, Entry 2). Prolonged the reaction time to 26 hours give higher 62% yield of the product 3d, but at solvent reflux temperature we isolated desired product at promising 73% yield (Table 1, Entries 3-4). Then we change solvent to CH₃CN, at solvent reflux temperature we obtained higher purity product with a little better 74% yield (Table 1, Entry 5). As such, the optimized CH₃CN solvent was tested using Cs₂CO₃ additive at 3 hours or 30 min. times, and at RT or under CH₃CN reflux temperature and geranyloxycoumarin 3d was formed with 93% or 87% yields, respectively (Table 1, Entries 6-7). The change base to more expensive silver(I) carbonate (Aq₂CO₃) give also good but low promising 85% yield of the product 3d (Table 1, Entry 8).

Table 1: Optimization of the reaction conditions for 7-geranyloxycoumarin (3d) preparation.

ОСОСОН	Base, Solvent	Londond
1d	3d	
Entry	Conditions	Yield (%)
1	Et ₃ N, acetone, RT, 12 h	degradation
2	K_2CO_3 , acetone, RT, 5 h	35
3	K ₂ CO ₃ , acetone, RT, 26 h	62
4	K ₂ CO ₃ , acetone, reflux, 1 h	73
5	K ₂ CO ₃ , CH ₃ CN, reflux, 1 h	74
6	Cs ₂ CO ₃ , CH ₃ CN, RT, 3 h	93
7	Cs ₂ CO ₃ , CH ₃ CN, reflux, 30 min	87
8	Ag ₂ CO ₃ , CH ₃ CN, RT, 3 h	85

Geranyloxycoumarin was synthesized in good yield by the reaction of hydroxycoumarin excluding 4-OH group and geranyl bromide under weak base and CH_3CN condition. In the cases where the OH group was positioned on the 3^{rd} , 5^{th} , 6^{th} , 7^{th} , or 8^{th} carbon of the coumarin structure, the reaction of

_

_

hydroxycoumarin (ex, 6-hydroxycoumarin) and geranyl bromide with cesium carbonate and acetonitrile at RT produced a high yield of *O*alkylated compounds. In this result, the reaction of

the different types of hydroxycoumarin and geranyl bromide under the given conditions produced various novel coumarin derivatives (Table 2).

HOOOO	$\frac{R^{1}-Br\left(2\right)}{Cs_{2}CO_{3},CH_{3}CN}$	0 0 - 0 - R ¹
1a ~ 11	R ¹⁻ Br : Br	3aa ~ 31

Table 2: Synthesized geranyloxycoumarin derivatives.

Entry	Coumarin	Time (h)	Product	Yield (%)
	OH			
1		3	3a	18
2	O ₂ N 1b	72	OR ¹ O ₂ N O O 3b	-
3	OF OH	3.5	OF OR ¹ 3c	90
4	O OH Id	3	OF OR ¹ 3d	94
5	OF OF OH	3	OF OR ¹ 3e	91
6	CI OH IF	4		93
7	CH ₃ Cl 1g	2.5	CH ₃ Cl OR ¹ 3g	90
8	C ₆ H ₅ Ih	3	C ₆ H ₅ 0 OR ¹ 3h	92
9	0 0 0 0 0 1i	3	OF OR ¹ 3i	92
10	O O I Ij	3	OF OR 3	89

62



^a.When 2 equivalents of geranyl bromide(2) are used.

Next, we studied the reaction of 4-hydroxycoumarin (1a) with geranyl bromide (2) to produce *O*-4 and C-3 alkylated products. Under optimized reaction conditions for *O*-alkylation, the desired 4-geranyloxycoumarin (3a) was obtained in low 18% yield. This reaction takes place on the tautomer A with the anion located on the oxygen atom in the C-4 position.

On the other hand, C-3 alkylated coumarin 3aa was formed in the reaction with 2 equivalents of geranyl bromide (2) started on the keto form tautomer B, with anion localized at C-3 carbon atom, with 11% yield. Moreover, compound 3ab was obtained in 35% yield by hydrolysis and decarboxylation from 3aa. We also confirmed that 3ab was obtained by adding 3aa to acetonitrile to which water was added and stirring at RT for 9 hours. These results are reported by Yi-Jen Shue et al. to obtain a C-alkylated coumarin and a diallylated product, which was hydrolyzed and then decarboxylated, by reacting 4-hydroxycoumarin and cinnamyl alcohol with water and palladium catalyst (Scheme 1) (37-40).



Scheme 1: Reactivity of 4-hydroxycoumarin.

No reaction occurred between 4-hydroxy-3nitrocoumarin (**1b**) and geranyl bromide (**2**) in Cs_2CO_3 , CH_3CN for 72 hours at RT or in reflux condition. It is expected that the desired product was not obtained by the reversible structure of 4hydroxy-3-nitrocoumarin of the nitro and nitrous types.

As can be seen, the alkylation reaction of hydroxycoumarin and geranyl bromide under mild

conditions led to a good yield; however, a new method of synthesis is required to achieve a higher yield of 4-geranyloxycoumarin. In addition, as the *O*-alkylated derivatives of geranyloxycoumarin are predicted to exhibit diverse bioactivities, further studies should be conducted on their synthesis.

REFERENCES

1. Borges F, Roleira F, Milhazes N, Santana L, Uriarte E. Simple Coumarins and Analogues in Medicinal Chemistry: Occurrence, Synthesis and Biological Activity. CMC. 2005 Apr 1;12(8):887–916. <<u>DOI></u>.

3. Berrino E, Milazzo L, Micheli L, Vullo D, Angeli A, Bozdag M, et al. Synthesis and Evaluation of Carbonic Anhydrase Inhibitors with Carbon Monoxide Releasing Properties for the Management of Rheumatoid Arthritis. J Med Chem. 2019 Aug 8;62(15):7233–49. Com/dol.com (DOI>.

4. Zhao Y-L, Yang X-W, Wu B-F, Shang J-H, Liu Y-P, Zhi-Dai, et al. Anti-inflammatory Effect of Pomelo Peel and Its Bioactive Coumarins. J Agric Food Chem. 2019 Aug 14;67(32):8810–8. <u><DOI></u>.

5. Peperidou A, Bua S, Bozdag M, Hadjipavlou-Litina D, Supuran C. Novel 6- and 7-Substituted Coumarins with Inhibitory Action against Lipoxygenase and Tumor-Associated Carbonic Anhydrase IX. Molecules. 2018 Jan 12;23(1):153. <<u>DOI></u>.

6. Chen LZ, Sun WW, Bo L, Wang JQ, Xiu C, Tang WJ, et al. New arylpyrazoline-coumarins: Synthesis and antiinflammatory activity. European Journal of Medicinal Chemistry. 2017 Sep;138:170–81. <u><DOI></u>.

7. Zhu M, Ma L, Wen J, Dong B, Wang Y, Wang Z, et al. Rational design and Structure–Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry. 2020 Jan;186:111900. <<u>DOI></u>.

8. Liu Y-P, Yan G, Xie Y-T, Lin T-C, Zhang W, Li J, et al. Bioactive prenylated coumarins as potential antiinflammatory and anti-HIV agents from Clausena lenis. Bioorganic Chemistry. 2020 Apr;97:103699. <<u>DOI</u>>.

9. Patil AD, Freyer AJ, Eggleston DS, Haltiwanger RC, Bean MF, Taylor PB, et al. The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian tree, Calophyllum inophyllum Linn. J Med Chem. 1993 Dec;36(26):4131–8. <<u>DOI></u>.

10. Zhao J-W, Wu Z-H, Guo J-W, Huang M-J, You Y-Z, Liu H-M, et al. Synthesis and anti-gastric cancer activity evaluation of novel triazole nucleobase analogues containing steroidal/coumarin/quinoline moieties. European Journal of Medicinal Chemistry. 2019 Nov;181:111520. <<u>DOI></u>.

11. Lin M-H, Wang J-S, Hsieh Y-C, Zheng J-H, Cho E-C. NO2 functionalized coumarin derivatives suppress cancer progression and facilitate apoptotic cell death in KRAS mutant colon cancer. Chemico-Biological Interactions. 2019 Aug;309:108708. <<u>DOI></u>.

12. Eker Y, Şenkuytu E, Ölçer Z, Yıldırım T, Çiftçi GY. Novel coumarin cyclotriphosphazene derivatives: Synthesis, characterization, DNA binding analysis with automated

biosensor and cytotoxicity. Journal of Molecular Structure. 2020 Jun;1209:127971. <<u>DOI></u>.

13. Sanduja M, Gupta J, Singh H, Pagare PP, Rana A. Uracil-coumarin based hybrid molecules as potent anticancer and anti-bacterial agents. Journal of Saudi Chemical Society. 2020 Feb;24(2):251–66. <<u>DOI></u>.

14. Ahmed EY, Abdel Latif NA, El-Mansy MF, Elserwy WS, Abdelhafez OM. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents. Bioorganic & Medicinal Chemistry. 2020 Mar;28(5):115328. <<u>DOI></u>.

15. Maly DJ, Leonetti F, Backes BJ, Dauber DS, Harris JL, Craik CS, et al. Expedient Solid-Phase Synthesis of Fluorogenic Protease Substrates Using the 7-Amino-4carbamoylmethylcoumarin (ACC) Fluorophore. J Org Chem. 2002 Feb 1;67(3):910–5. <<u>DOI></u>.

16. Koparde S, Hosamani KM, Barretto DA, Joshi SD. Microwave synthesis of coumarin-maltol hybrids as potent antitumor and anti-microbial drugs: An approach to molecular docking and DNA cleavage studies. Chemical Data Collections. 2018 Aug;15–16:41–53. <<u>DOI></u>.

17. Ostrowska K. Coumarin-piperazine derivatives as biologically active compounds. Saudi Pharmaceutical Journal. 2020 Feb;28(2):220–32. <<u>DOI></u>.

18. Smyth T, Ramachandran VN, Smyth WF. A study of the antimicrobial activity of selected naturally occurring and synthetic coumarins. International Journal of Antimicrobial Agents. 2009 May;33(5):421–6. <<u>DOI></u>.

19. Wang H, Xu W. Mito-methyl coumarin, a novel mitochondria-targeted drug with great antitumor potential was synthesized. Biochemical and Biophysical Research Communications. 2017 Jul;489(1):1–7. <<u>DOI></u>.

20. Weber US, Steffen B, Siegers CP. Antitumor-activities of coumarin, 7-hydroxy-coumarin and its glucuronide in several human tumor cell lines. Res Commun Mol Pathol Pharmacol. 1998 Feb;99(2):193–206. <u><URL></u>.

21. Liu H, Li Z, Yu L, Zhang Y. Antitumor activity and mechanisms of scoparone. J Zhong Guo Yao Li Tong Xun. 2005;22:40–1.

22. Liu W, Hua J, Zhou J, Zhang H, Zhu H, Cheng Y, et al. Synthesis and in vitro antitumor activity of novel scopoletin derivatives. Bioorganic & Medicinal Chemistry Letters. 2012 Aug;22(15):5008–12. >DOI>.

23. Zaragozá C, Monserrat J, Mantecón C, Villaescusa L, Zaragozá F, Álvarez-Mon M. Antiplatelet activity of flavonoid and coumarin drugs. Vascular Pharmacology. 2016 Dec;87:139–49. <<u>DOI></u>.

24. Revankar HM, Bukhari SNA, Kumar GB, Qin H-L. Coumarins scaffolds as COX inhibitors. Bioorganic Chemistry. 2017 Apr;71:146–59. <u><DOI></u>.

25. Huang H-Y, Ko H-H, Jin Y-J, Yang S-Z, Shih Y-A, Chen I-S. Dihydrochalcone glucosides and antioxidant activity from the roots of Anneslea fragrans var. lanceolata. Phytochemistry. 2012 Jun;78:120–5. <<u>DOI></u>.

26. Khan S, Riaz N, Afza N, Malik A, Aziz-ur-Rehman, Iqbal L, et al. Antioxidant constituents from Cotoneaster racemiflora. Journal of Asian Natural Products Research. 2009 Jan 1;11(1):44–8. <<u>DOI></u>.

27. Mangasuli SN, Hosamani KM, Managutti PB. Microwave assisted synthesis of coumarin-purine derivatives: An approach to in vitro anti-oxidant, DNA cleavage, crystal structure, DFT studies and Hirshfeld surface analysis. Heliyon. 2019 Jan;5(1):e01131. <a href="https://www.commonstaticticscommonstaticsco

28. Ambreen, Haque S, Singh V, Katiyar D, Ali Khan MT, Tripathi V, et al. Biotransformation of newly synthesized coumarin derivatives by Candida albicans as potential antibacterial, antioxidant and cytotoxic agents. Process Biochemistry. 2019 Dec;87:138–44. <u><DOI></u>.

29. Kavetsou E, Gkionis L, Galani G, Gkolfinopoulou C, Argyri L, Pontiki E, et al. Synthesis of prenyloxy coumarin analogues and evaluation of their antioxidant, lipoxygenase (LOX) inhibitory and cytotoxic activity. Med Chem Res. 2017 Apr;26(4):856–66. <u><DOI></u>.

30. Roussaki M, Zelianaios K, Kavetsou E, Hamilakis S, Hadjipavlou-Litina D, Kontogiorgis C, et al. Structural modifications of coumarin derivatives: Determination of antioxidant and lipoxygenase (LOX) inhibitory activity. Bioorganic & Medicinal Chemistry. 2014 Dec;22(23):6586–94. <<u>DOI></u>.

31. Al-Majedy Y, Al-Duhaidahawi D, Al-Azawi K, Al-Amiery A, Kadhum A, Mohamad A. Coumarins as Potential Antioxidant Agents Complemented with Suggested Mechanisms and Approved by Molecular Modeling Studies. Molecules. 2016 Jan 23;21(2):135. > Notestinuation.com

32. Yun B-S, Lee I-K, Ryoo I-J, Yoo I-D. Coumarins with Monoamine Oxidase Inhibitory Activity and Antioxidative Coumarino-lignans from Hibiscus s yriacus. J Nat Prod. 2001 Sep 1;64(9):1238–40. .

33. Tamene D, Endale M. Antibacterial Activity of Coumarins and Carbazole Alkaloid from Roots of Clausena anisata. Advances in Pharmacological Sciences. 2019 Feb 3;2019:1–8. >DOI>.

34. Yang L, Wu L, Yao X, Zhao S, Wang J, Li S, et al. Hydroxycoumarins: New, effective plant-derived compounds reduce Ralstonia pseudosolanacearum populations and control tobacco bacterial wilt. Microbiological Research. 2018 Oct;215:15–21. <<u>DOI></u>.

35. Ramírez-Pelayo C, Martínez-Quiñones J, Gil J, Durango D. Coumarins from the peel of citrus grown in Colombia: composition, elicitation and antifungal activity. Heliyon. 2019 Jun;5(6):e01937. <<u>DOI></u>.

36. Shah V, Bose J, Shah R. Communication- New Synthesis of 4-Hydroxycoumarins. J Org Chem. 1960 Apr;25(4):677–8. <a href="https://www.communication-communicatio-communicatio-communicatio-communicatio-communicatio-communicatio

37. Cravotto G, Nano GM, Palmisano G, Tagliapietra S. 4-Hydroxycoumarin and related systems: Sitoselectivity of the mitsunobu reaction with prenyl alcohols. HETEROCYCLES. 2003;60:1351–8. <<u>URL></u>.

38. Patra P. 4-Chloro-3-formylcoumarin as a multifaceted building block for the development of various bio-active

substituted and fused coumarin heterocycles: a brief review. New J Chem. 2021;45(32):14269–327. <<u>DOI></u>.

39. Russell A, Frye JR. 2,6-dihydroxyacetophenone. Org Synth. 1941;21:22. <<u>DOI></u>.

40. Shue Y-J, Yang S-C. Activator-free and one-pot C-allylation by simple palladium catalyst in water. Tetrahedron Letters. 2012 Mar;53(11):1380–4. <<u>DOI></u>.

41. Woods LL, Sapp J. A New One-Step Synthesis of Substituted Coumarins. J Org Chem. 1962 Oct;27(10):3703-5. <<u>DOI></u>.

42. Venturella P, Bellino A, Marino M, Maria L. Synthesis of terpenoid coumarins, an approach to the synthesis of Piloselliodan. Gazz Chim Italiana. 1982;112(9/10):433-4.

43. Iranshahi M, Jabbari A, Orafaie A, Mehri R, Zeraatkar S, Ahmadi T, et al. Synthesis and SAR studies of mono Oprenylated coumarins as potent 15-lipoxygenase inhibitors. European Journal of Medicinal Chemistry. 2012 Nov;57:134–42. <<u>DOI></u>.

44. Khomenko TM, Zarubaev VV, Orshanskaya IR, Kadyrova RA, Sannikova VA, Korchagina DV, et al. Antiinfluenza activity of monoterpene-containing substituted coumarins. Bioorganic & Medicinal Chemistry Letters. 2017 Jul;27(13):2920–5. <<u>DOI></u>.

45. Orhan IE, Senol Deniz FS, Salmas RE, Durdagi S, Epifano F, Genovese S, et al. Combined molecular modeling and cholinesterase inhibition studies on some natural and semisynthetic O-alkylcoumarin derivatives. Bioorganic Chemistry. 2019 Mar;84:355–62. <<u>DOI></u>.